[{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"SynOx Therapeutics raises \u20ac37M in Series A Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Emactuzumab Designated as an Orphan Medicinal Product in Europe","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Forbion","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"SynOx Therapeutics Announces $75m Series B Round to Fund Phase 3 Trial of Potential Best-in-class Treatment for TGCT","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"SynOx Therapeutics","sponsor":"Hercules Capital","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"SynOx Therapeutics Secures up to $35m Debt Financing with Hercules Capital to Progress Development and Commercialisation of Emactuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"IRELAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by SynOx Therapeutics
The financing is intended to support the clinical development of Synox's late-stage product and the commercialization of emactuzumab for treating Tenosynovial Giant Cell Tumor.
The proceeds will be used to advance late-stage product Emactuzumab, SynOx's potentially best-in-class CSF-1(R) inhibiting monoclonal antibody for the treatment of Tenosynovial Giant Cell Tumour.
Emactuzumab is a novel monoclonal antibody inhibiting CSF-1R that offers a short course of treatment. Phase I/II studies indicated good tolerability and a manageable safety profile and substantial preliminary efficacy in TGCT patients.
The financing will enable SynOx to continue the development of emactuzumab, for the treatment of diffuse tenosynovial giant cell tumours (“TGCT”), also known as pigmented villonodular synovitis (”PVNS”), and other indications.